Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement

Despite highly efficacious antiretroviral therapy (ART), durable ART-free remission remains a central objective of HIV-1 cure strategies. The randomized, placebo-controlled RIO trial recently demonstrated that long-acting broadly neutralizing anti-HIV-1 antibodies (bNAbs) can sustain prolonged virologic control after ART interruption, including control that persisted beyond the period of therapeutically relevant antibody concentrations, providing clinical evidence consistent with host-mediated suppression. However, the mechanisms underlying these "vaccinal" effects remain unresolved. Here, we establish Fcγ receptor (FcγR) engagement as an essential driver of multiyear remission after bNAb therapy in simian-human immunodeficiency virus (SHIV)-infected macaques. Brief therapy during acute infection with Fc domain variants of the bNAb 3BNC117, matched for antigen binding, neutralizing activity, and pharmacokinetics but differing in FcγR engagement, produced comparable early virologic control yet profoundly divergent long-term outcomes. Sustained CD8 T cell-dependent suppression lasting nearly 300 wk developed in every evaluable animal receiving the FcγR-engaging variant but arose in only one of eight recipients of the FcγR-null variant. FcγR-driven immunomodulation imprinted a CD8 T cell response characterized by enhanced antigen-specific effector function, early clonal focusing with sustained clonotype persistence, and distinct cellular-state transcriptional signatures. Our findings identify the Fc-FcγR axis as a critical determinant of the reliable induction of durable remission and provide a mechanistic framework for developing Fc-engineered bNAbs designed to enhance vaccinal immunity and advance antibody-based strategies with the potential to achieve functional cure.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2026-11-17
DOI
https://doi.org/10.1073/pnas.2632384123
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement

Jeffrey V. Ravetch, Daniel C. Rogan, Stylianos Bournazos, Reza Sadjadpour et al.
2 links
Proceedings of the National Academy of Sciences
HIV Research and Treatment
article

Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement

Jeffrey V. Ravetch, Daniel C. Rogan, Stylianos Bournazos, Reza Sadjadpour, Mark Connors, Yoshiaki Nishimura, Eric Jesteadt, Paulina A. Przygonska, Emily G. Niejadlik, Tyler Meeks, Jonathan D Webber, Hadrien Lehman, Veronica E. Minster, Malcolm A. Martin, Barbara Ann C. Grace
article en

Abstract

Despite highly efficacious antiretroviral therapy (ART), durable ART-free remission remains a central objective of HIV-1 cure strategies. The randomized, placebo-controlled RIO trial recently demonstrated that long-acting broadly neutralizing anti-HIV-1 antibodies (bNAbs) can sustain prolonged virologic control after ART interruption, including control that persisted beyond the period of therapeutically relevant antibody concentrations, providing clinical evidence consistent with host-mediated suppression. However, the mechanisms underlying these "vaccinal" effects remain unresolved. Here, we establish Fcγ receptor (FcγR) engagement as an essential driver of multiyear remission after bNAb therapy in simian-human immunodeficiency virus (SHIV)-infected macaques. Brief therapy during acute infection with Fc domain variants of the bNAb 3BNC117, matched for antigen binding, neutralizing activity, and pharmacokinetics but differing in FcγR engagement, produced comparable early virologic control yet profoundly divergent long-term outcomes. Sustained CD8 T cell-dependent suppression lasting nearly 300 wk developed in every evaluable animal receiving the FcγR-engaging variant but arose in only one of eight recipients of the FcγR-null variant. FcγR-driven immunomodulation imprinted a CD8 T cell response characterized by enhanced antigen-specific effector function, early clonal focusing with sustained clonotype persistence, and distinct cellular-state transcriptional signatures. Our findings identify the Fc-FcγR axis as a critical determinant of the reliable induction of durable remission and provide a mechanistic framework for developing Fc-engineered bNAbs designed to enhance vaccinal immunity and advance antibody-based strategies with the potential to achieve functional cure.

Proceedings of the National Academy of SciencesVol. 123(47)
National Institutes of Health (US), National Institute of Allergy and Infectious Diseases (US), Rockefeller University (US)
U.S. Department of Health and Human Services, amfAR, The Foundation for AIDS Research, National Institutes of Health, National Institute of Allergy and Infectious Diseases, NHLBI Division of Intramural Research
Good health and well-being
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon